Obiettivo
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need.
The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.
Campo scientifico
Argomento(i)
Invito a presentare proposte
IMI-JU-06-2012
Vedi altri progetti per questo bando
Meccanismo di finanziamento
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Coordinatore
151 85 Sodertaelje
Svezia
Mostra sulla mappa
Partecipanti (38)
3584 CX Utrecht
Mostra sulla mappa
1200 Bruxelles / Brussel
Mostra sulla mappa
50937 Koeln
Mostra sulla mappa
87000 Limoges
Mostra sulla mappa
08036 Barcelona
Mostra sulla mappa
Partecipazione conclusa
25030 BESANCON CEDEX
Mostra sulla mappa
38124 Braunschweig
Mostra sulla mappa
75654 Paris
Mostra sulla mappa
2000 Antwerpen
Mostra sulla mappa
1211 Geneve
Mostra sulla mappa
3703 CD Zeist
Mostra sulla mappa
79106 Freiburg
Mostra sulla mappa
Partecipazione conclusa
1011 Lausanne
Mostra sulla mappa
Partecipazione conclusa
6525 XZ Nijmegen
Mostra sulla mappa
BS10 5NB Bristol
Mostra sulla mappa
Partecipazione conclusa
38041 GRENOBLE
Mostra sulla mappa
WC1A 1DG LONDON
Mostra sulla mappa
2340 Beerse
Mostra sulla mappa
41071 Sevilla
Mostra sulla mappa
97159 Pointe-à-Pitre Pointe-à-Pitre
Mostra sulla mappa
581 83 Linkoping
Mostra sulla mappa
10561 Athina
Mostra sulla mappa
72074 Tuebingen
Mostra sulla mappa
17489 Greifswald
Mostra sulla mappa
69622 Villeurbanne Cedex
Mostra sulla mappa
3015 GD Rotterdam
Mostra sulla mappa
08036 Barcelona
Mostra sulla mappa
28046 MADRID
Mostra sulla mappa
64239 Tel Aviv
Mostra sulla mappa
1649-016 Lisboa
Mostra sulla mappa
7270 Davos
Mostra sulla mappa
20122 Milano
Mostra sulla mappa
75014 Paris
Mostra sulla mappa
8006 Zurich
Mostra sulla mappa
75011 PARIS
Mostra sulla mappa
07054 Parsippany
Mostra sulla mappa
CT13 9NJ Sandwich
Mostra sulla mappa
1050 Bruxelles / Brussel
Mostra sulla mappa